BioXcel Therapeutics (FRA:BX2) Long-Term Debt : €93.50 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics Long-Term Debt?

BioXcel Therapeutics's Long-Term Debt for the quarter that ended in Mar. 2024 was €93.50 Mil.

BioXcel Therapeutics's quarterly Long-Term Debt declined from Sep. 2023 (€92.85 Mil) to Dec. 2023 (€92.25 Mil) but then increased from Dec. 2023 (€92.25 Mil) to Mar. 2024 (€93.50 Mil).

BioXcel Therapeutics's annual Long-Term Debt increased from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€87.84 Mil) and increased from Dec. 2022 (€87.84 Mil) to Dec. 2023 (€92.25 Mil).

BioXcel Therapeutics Long-Term Debt Historical Data

The historical data trend for BioXcel Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioXcel Therapeutics Long-Term Debt Chart

BioXcel Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

87.84

92.25

BioXcel Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Debt	Get a 7-Day Free Trial															88.79	89.39	92.85	92.25	93.50

BioXcel Therapeutics (FRA:BX2) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

BioXcel Therapeutics Long-Term Debt Related Terms

Thank you for viewing the detailed overview of BioXcel Therapeutics's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

BioXcel Therapeutics (FRA:BX2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (FRA:BX2) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

BTAI:USA BX2:Germany

Address

555 Long Wharf Drive, 12th Floor, New Haven, CT, USA, 06511

Website

https://www.bioxceltherapeutics.com

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

BioXcel Therapeutics (FRA:BX2) Headlines

No Headlines